Overview

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
Phase:
Phase 3
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Collaborator:
Parexel
Treatments:
Rotigotine